Travere Therapeutics (TVTX) Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Travere Therapeutics (TVTX) PT Raised to $18 at Barclays
September 30, 2024 6:13 AM EDTBarclays analyst Carter Gould raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $18.00 (from $14.00) while maintaining a Overweight rating.
The analyst comments "Forthcoming FSGS updates should provide steady set of catalysts de-risking regulatory path (adding $300mn+ to U.S. peak sales potential, and... More
Travere Therapeutics (TVTX) PT Lowered to $19 at Citi
September 27, 2024 7:23 AM EDTCiti analyst Carly Kenselaar lowered the price target on Travere Therapeutics (NASDAQ: TVTX) to $19.00 (from $23.00) while maintaining a Buy rating.
The analyst comments "The enrollment pause in the Ph3 HCU trial triggered by the pegtibatinase manufacturing scale-up not meeting required specs is obviously... More
